Eisai Co Ltd Spons A (ESALY) 59.5560 $ESALY Drug Stocks'

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Eisai Co Ltd Spons A (ESALY) 59.5560 $ESALY

Drug Stocks' Earnings Slated for This Week: RDY, AVXS, ESALY
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:03AM CDT
Quite a few companies are still yet to report results. Let's take a peek at a few drug stocks that will report quarterly results later this week
JNJ: 116.99 (+1.19), GILD: 85.89 (-1.53), PFE: 35.43 (+0.18), AMGN: 156.73 (-1.27), ABBV: 60.60 (-1.13), RDY: 45.81 (-1.06), AVXS: 44.99 (+1.34), NVS: 80.56 (-0.83)

Jazz (JAZZ) Q1 Earnings: A Beat in the Cards for the Stock?
Zacks Equity Research - Zacks Investment Research - Fri May 06, 4:13PM CDT
Jazz Pharmaceuticals (JAZZ), which is set to report first-quarter 2016 results on May 10, delivered a positive earnings surprise of 36.75% last quarter.
IPXL: 33.38 (-0.28), CLSN: 1.42 (+0.01), JAZZ: 155.51 (+0.55)

Corcept's (CORT) Q4 Earnings Impress, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Wed Mar 02, 10:00AM CST
Corcept Therapeutics Incorporated (CORT) reported earnings of 1 cent per share in the fourth quarter of 2015, while Zacks Consensus Estimates was a loss of 2 cents
PETX: 7.11 (-0.29), TRIL: 9.98 (-0.71), CORT: 5.37 (-0.27)

Halozyme Raises Funds to Support Ongoing Oncology Studies
Zacks Equity Research - Zacks Investment Research - Tue Jan 05, 3:55PM CST
Halozyme (HALO) announced that it has entered into a $150 million credit agreement secured by future royalties from Enhanze products, which Halozyme is entitled to receive from its collaborations with Roche and Baxalta, Inc.
HALO: 8.98 (-0.23), BXLT: 46.02 (-0.18)

Arena (ARNA)/Eisai's Belviq XR NDA Accepted for Review
Arpita Dutt - Zacks Investment Research - Tue Dec 01, 3:32PM CST
Arena (ARNA) is looking to get a once-daily formulation of its chronic weight management treatment approved in the U.S.
ACHN: 9.82 (+0.21), BXLT: 46.02 (-0.18), ARNA: 2.11 (-0.04)

Arena 3Q Loss Narrower-Than-Expected, Belviq in Focus
Arpita Dutt - Zacks Investment Research - Wed Nov 11, 9:34AM CST
Arena (ARNA) is looking to cut costs and improve efficiency through a restructuring plan.
ACHN: 9.82 (+0.21), BXLT: 46.02 (-0.18), ARNA: 2.11 (-0.04)

Jazz's Q3 Earnings & Revenues Grow Y/Y; Trims 2015 Outlook
Zacks Equity Research - Zacks Investment Research - Wed Nov 11, 8:30AM CST
Jazz Pharmaceuticals (JAZZ) reported third-quarter 2015 adjusted earnings of $2.16 per share, up 7.5% year over year.
JAZZ: 155.51 (+0.55), TEVA: 53.44 (-0.55), CNCE: 13.05 (-0.25)

Corcept's Q2 Loss Narrower than Expected, View Narrowed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 06, 10:35AM CDT
Corcept Therapeutics (CORT) posted loss of a penny per share in the second quarter of 2015, narrower than both the Zacks Consensus Estimate of a loss of 5 cents.
VRX: 24.88 (+0.96), ANAC: 99.05 (-0.14), CORT: 5.37 (-0.27)

Arena Pharmaceuticals 2Q Loss Narrower-Than-Expected - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Aug 06, 8:10AM CDT
Although Arena Pharmaceuticals' (ARNA) second quarter loss was narrower-than-expected, revenues missed expectations.
GILD: 85.89 (-1.53), ARNA: 2.11 (-0.04)

Will Epizyme (EPZM) Pull a Surprise this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 05, 12:40PM CDT
Epizyme (EPZM) has an Earnings ESP of 3.08% with a Zacks Rank #2 and is scheduled to report its second-quarter 2015 results on Aug 6.
INO: 11.11 (-0.13), EPZM: 12.40 (-0.59), GSK: 42.06 (-0.45)

Will Arena Pharmaceuticals (ARNA) Surprise Q2 Earnings? - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 04, 12:00PM CDT
Investor focus will remain on the performance of Arena's (ARNA) obesity treatment - Belviq.
BDSI: 2.89 (-0.03), VVUS: 1.21 (-0.06), ARNA: 2.11 (-0.04)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Boston STEM Expo Sparks Young Minds in Engineering

Updated Category News Views 243

If you really want to light up a kid's imagination, throw them into a room full of science experiments and let 'em have at it. That's exactly what happened at the recent Society of Women Engineers' Innovation Expo in Boston's Seaport District. The place was buzzing, and not just because of all the engineering gadgets on display—it was the energy of young minds...

Continue Reading
Off-Broadway Play 'DUST' Raises Autism Support Funds

Updated Category News Views 476

Here's the scoop: an Off-Broadway production just did something many big hitters can't pull off. 'DUST,' a show crafted like a love letter to the American West, managed to rustle up $30,000 for young adults grappled with autism. Partnering with no less than Yale's Cultural Autism Studies and the Ed Asner Family Center, this effort hit the mark in more ways than one. An...

Continue Reading
NatGold Pulling NATG From MEXC Amid Security Concerns

Updated Category News Views 599

NatGold Digital's sudden decision to yank its NATG token off MEXC Global reeks of regulatory urgency. With the U.S. Treasury clamping down on fund transfers wrapping up MEXC in their action against Russian laundering, NatGold didn't wait for the ink to dry on that order. They’re off the exchange posthaste. A bit of foresight or sheer necessity? Well, it's got the market...

Continue Reading
Historic Records Set at 2026 CNO Monumental Marathon

Updated Category News Views 446

Race to Remember: Monumental Breakthroughs In the chilly November air of Indianapolis, the 2026 CNO Financial Indianapolis Monumental Marathon wasn't just another tick on the calendar—this was a banner day for running. With record-breaking performances across every distance, we saw what happens when a community of athletes, sponsors, and volunteers hits a perfect...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 16

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
2027 Toy of the Year Finalists Energize Play Market

Updated Category News Views 308

A Kaleidoscope of Innovation in Toys There's a familiar buzz in the air, folks. The 2027 Toy of the Year Awards finalists have been unveiled, and they're bringing a fresh wave of creativity to children's playrooms. These aren't just toys; they're miniature innovators ready to light up the market this holiday season. The reveal happened at the Chicago Toy & Game Fair and...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 253

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 56

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Invasive Procedures Don't Extend Life in Stable Heart Disease

Updated Category News Views 477

Challenging Longstanding Beliefs Today’s news from the heart research front might set a few cardiology heads spinning. We’ve got big-time findings out of the ISCHEMIA-EXTEND study, throwing more weight on the evidence pile that early invasive heart procedures for patients with stable coronary artery disease don’t actually extend your life. Managing care with a blend...

Continue Reading
Evaluating GLP-1 Telehealth? Key Questions to Consider

Updated Category News Views 572

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Growing Market for IBS Treatments by 2033

Updated Category News Views 225

Understanding Irritable Bowel Syndrome and Its Impact Irritable bowel syndrome (IBS) represents a widespread digestive disorder affecting numerous individuals around the globe. Symptoms may include abdominal discomfort, altered bowel habits, and physical distress. This condition can hamper daily activities and significantly impact the quality of life for those affected....

Continue Reading
Trucordia Partners with Vertafore to Streamline Operations

Updated Category News Views 181

Trucordia Partners with Vertafore for Operational Integration In an exciting move within the insurance industry, Trucordia has decided to partner with Vertafore to strengthen its operational framework and prepare for future growth. This strategic alliance aims to leverage modern technology to unify Trucordia's multitude of locations, providing a foundation for enhanced...

Continue Reading
Goodyear Raises $1.05B Amid Rising Interest Rates

Updated Category News Views 12

Goodyear's Bold Financing Move in a Challenging Market When you're in the shoe business, borrowing a billion bucks isn't everyday business, yet that's exactly what Goodyear Tire & Rubber Company just pulled off. Sure, the smell of rubber and burnt coffee might greet you at their Akron HQ, but what's really brewing is high-stakes financial maneuvering. They've priced $1.05...

Continue Reading
Fortive Delivers Mixed Q3 Results with Adjusted EPS Beat

Updated Category News Views 108

Fortive Corporation Reports Mixed Results in Q3 Fortive Corporation (NYSE: FTV) recently announced its third-quarter financial results, revealing some challenges alongside positive developments. Following the report, Fortive's shares have seen a decrease as investors digest the mixed outcomes. Quarterly Performance Overview During this quarter, Fortive's revenue...

Continue Reading
Investors Urged to Act on Constellation Brands Class Action

Updated Category News Views 98

Faruqi & Faruqi Invites Investors’ Attention Faruqi & Faruqi, LLP, a distinguished national securities law firm, is reaching out to investors regarding a significant class action lawsuit involving Constellation Brands, Inc. (NYSE: STZ). With the deadline for potential lead plaintiffs approaching on April 21, 2025, it is essential for affected investors to act swiftly...

Continue Reading